Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel Truniger

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Therapeutische Umschau. Revue Therapeutique|December 14, 2023
[Modern endoscopy in inflammatory bowel disease]Samuel Truniger, Remus Frei, Stephan Brand
Case Reports in Gastroenterology|August 25, 2025
First Description of Upadacitinib as Treatment for Collagenous Colitis with a Concomitant Lymphocytic Disorder of the Upper Gastrointestinal TractSamuel Truniger, Jan Borovicka, Marius König, et al.
ACG Case Reports Journal|May 21, 2025
First Description of Simultaneous Sweet Syndrome and Tracheal Stenosis as Extraintestinal Manifestations in a Patient With Highly Active Ulcerative ColitisHala Alrasheed, Oray Kahraman, Eva Markert, et al.
Plos One|July 28, 2020
Development of a uniform, very aggressive disease phenotype in all homozygous carriers of the NOD2 mutation p.Leu1007fsX1008 with Crohn's disease and active smoking status resulting in ileal stenosis requiring surgeryFabian Schnitzler, Matthias Friedrich, Marianne Angelberger, et al.
Alimentary Pharmacology & Therapeutics|October 29, 2022
Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2Simon Woelfel, Joel Dütschler, Marius König, et al.
Vaccines|July 30, 2025
XBB.1.5 COVID-19 mRNA Vaccines Induce Inadequate Mucosal Immunity in Patients with Inflammatory Bowel DiseaseSimon Woelfel, Joel Dütschler, Daniel Junker, et al.
Alimentary Pharmacology & Therapeutics|October 29, 2024
XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel DiseaseSimon Woelfel, Joel Dütschler, Daniel Junker, et al.
Vaccines|July 27, 2024
Systemic and Mucosal Immunogenicity of Monovalent XBB.1.5-Adapted COVID-19 mRNA Vaccines in Patients with Inflammatory Bowel DiseaseSimon Woelfel, Joel Dütschler, Daniel Junker, et al.
Alimentary Pharmacology & Therapeutics|August 12, 2023
STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel diseaseSimon Woelfel, Joel Dütschler, Marius König, et al.
Vaccines|November 26, 2024
STAR LIGHT Study: XBB.1.5 COVID-19 mRNA Vaccines Boost Systemic but Not Mucosal Immunity Against the SARS-CoV-2 JN.1 Variant in Patients with Chronic Liver DiseaseSimon Woelfel, Daniel Junker, Irina Bergamin, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Therapeutische Umschau. Revue Therapeutique|December 14, 2023
[Modern endoscopy in inflammatory bowel disease]Samuel Truniger, Remus Frei, Stephan Brand
Case Reports in Gastroenterology|August 25, 2025
First Description of Upadacitinib as Treatment for Collagenous Colitis with a Concomitant Lymphocytic Disorder of the Upper Gastrointestinal TractSamuel Truniger, Jan Borovicka, Marius König, et al.
ACG Case Reports Journal|May 21, 2025
First Description of Simultaneous Sweet Syndrome and Tracheal Stenosis as Extraintestinal Manifestations in a Patient With Highly Active Ulcerative ColitisHala Alrasheed, Oray Kahraman, Eva Markert, et al.
Plos One|July 28, 2020
Development of a uniform, very aggressive disease phenotype in all homozygous carriers of the NOD2 mutation p.Leu1007fsX1008 with Crohn's disease and active smoking status resulting in ileal stenosis requiring surgeryFabian Schnitzler, Matthias Friedrich, Marianne Angelberger, et al.
Alimentary Pharmacology & Therapeutics|October 29, 2022
Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2Simon Woelfel, Joel Dütschler, Marius König, et al.
Vaccines|July 30, 2025
XBB.1.5 COVID-19 mRNA Vaccines Induce Inadequate Mucosal Immunity in Patients with Inflammatory Bowel DiseaseSimon Woelfel, Joel Dütschler, Daniel Junker, et al.
Alimentary Pharmacology & Therapeutics|October 29, 2024
XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel DiseaseSimon Woelfel, Joel Dütschler, Daniel Junker, et al.
Vaccines|July 27, 2024
Systemic and Mucosal Immunogenicity of Monovalent XBB.1.5-Adapted COVID-19 mRNA Vaccines in Patients with Inflammatory Bowel DiseaseSimon Woelfel, Joel Dütschler, Daniel Junker, et al.
Alimentary Pharmacology & Therapeutics|August 12, 2023
STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel diseaseSimon Woelfel, Joel Dütschler, Marius König, et al.
Vaccines|November 26, 2024
STAR LIGHT Study: XBB.1.5 COVID-19 mRNA Vaccines Boost Systemic but Not Mucosal Immunity Against the SARS-CoV-2 JN.1 Variant in Patients with Chronic Liver DiseaseSimon Woelfel, Daniel Junker, Irina Bergamin, et al.
Pageof 1